Visualization Of The Insertion Site

Protective Disk with CHG

IF YOU
VISUALIZE
THE SITE,
WHAT ARE
YOU
LOOKING
FOR?

WHAT IS THE CLINICAL SIGNIFICANCE?

WHY?

LOCAL SIGNS OF INFECTION

EDEMA/SWELLING	TOUCH
INDURATION/HARDENING	TOUCH
TENDERNESS	тоисн
HEAT	TOUCH
ERYTHEMA/REDNESS	VISUAL

The conclusion of the combination of 2 randomized trials involving 1,263 central venous catheter was:

"The sensitivity of local infection for the diagnosis of CVC-related BSI was dismal (0-3%)." Safdar/Maki 1

Inflammation at the insertion site is not indicative of infection at the insertion site. Many types of bacteria responsible for CRBSI do not cause visible site reaction (ie, coagulase negative staph bacteria). Safdar/Maki ¹

Over the past 15 years BIOPATCH® Protective Disk with CHG has been evaluated in multiple studies and controlled randomized trials. It is the only device of its kind with an FDA-cleared indication to reduce local infections, catheter-associated bloodstream infections (CRBSI), and skin colonization of microorganisms

commonly related to CRBSI, in patients with central venous or arterial catheters.

ETHICO N, INC.

a formion of ormion company


Please visit www.biopatch.com for Full Prescribing Information

References: 1. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. *Intensive Care Med.* 2004;30:62-67 **2.** O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 2002 Aug 9;51(RR-10):1-29.


ETHICON Inc. 2009, BP-078

TRYING TO SEE ERYTHEMA OR REDNESS FOR ASSESSMENT OF EXIT SITE INFECTION?


2002 CDC GUIDELINES <u>FOR THE PREVENTION</u>
<u>OF INTRAVASCULAR CATHETER-RELATED</u>
<u>INFECTIONS</u>² defines the following:



"Erythema, or induration within 2 cm from the catheter exit site, in the absence of concomitant bloodstream infection (BSI) and without concomitant purulence"



"Tenderness, erythema, or site induration >2 cm from the catheter site along the subcutaneous tract of a tunneled (eg, Hickman or Broviac) catheter, in the absence of concomitant BSI"



BIOPATCH® does not interfere with visualization of clinically relevant erythema as defined by the CDC